Antitumor effect of a novel phenanthroindolizidine alkaloid derivative through inhibition of protein synthesis

Anticancer Res. 2014 Jul;34(7):3391-7.

Abstract

Aim: The present study aimed to determine the antitumor efficacy of a new Phenanthroindolizidine alkaloid (PA) derivative, YPC-10157, and to elucidate its mechanism of action.

Materials and methods: The in vitro and in vivo antitumor activity of YPC-10157 was evaluated against several human cancer cell lines and mouse xenograft models, respectively. Cell apoptosis was determined by measuring caspase-3/7 activity. The effect on protein synthesis was assessed using an in vitro cell-free translation assay system.

Results: In vitro, YPC-10157 exhibited marked cell growth inhibition and induced apoptosis. In vivo, YPC-10157 had a strong antitumor effect on xenograft models of human colon cancer and leukemia. Moreover, YPC-10157 and its derivatives inhibited protein synthesis and their inhibitory activity on protein synthesis significantly correlated regarding cell growth.

Conclusion: YPC-10157 has promising antitumor effects and suggest that its cytotoxic mechanism might involve the inhibition of protein synthesis.

Keywords: Phenanthroindolizine alcaloid; YPC-10157; antitumor activity; caspase activity.

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology*
  • Apoptosis / drug effects
  • Cell Line, Tumor
  • HCT116 Cells
  • HL-60 Cells
  • HT29 Cells
  • Humans
  • Indole Alkaloids / pharmacology*
  • Indolizines / pharmacology*
  • MCF-7 Cells
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Mice, Nude
  • Phenanthrolines / pharmacology*
  • Protein Synthesis Inhibitors / pharmacology*
  • Random Allocation
  • Xenograft Model Antitumor Assays

Substances

  • Antineoplastic Agents
  • Indole Alkaloids
  • Indolizines
  • Phenanthrolines
  • Protein Synthesis Inhibitors
  • phenanthroindolizidine